XML 84 R61.htm IDEA: XBRL DOCUMENT v3.23.2
SHARE-BASED COMPENSATION PLANS (Tables)
 12 Months Ended
Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of share-based compensation expense
Total share-based compensation from continuing operations is shown in the table below:
202320222021
Equity plan expense (a)
$134.7 $195.4 $25.4 
Equity plan modified and cash settled— — 0.9 
Liability plan expense (income)1.2 0.1 1.6 
Fringe expense1.7 2.3 0.5 
Total share-based compensation expense(b)
$137.6 $197.8 $28.4 
(a) Equity plan shared-based compensation expense of $134.7, $195.4, and $27.4 was recorded to additional paid in capital and presented in the Consolidated Statement of Equity for the fiscal years ended June 30, 2023, 2022, and 2021, respectively. Of the $134.7, $195.4, and $27.4 for the fiscal years ended June 30, 2023, 2022, and 2021, respectively, $0.0, $0.0, and $2.0 was reclassified to discontinued operations. (b)Expenses relating to share-based awards granted to non-Coty employees (Wella) are recorded within other income, net, within the Consolidated Statement of Operations. See Note 27 -Related Party Transactions for additional information.
Schedule of fair value valuation assumptions The fair value of the Company’s outstanding Series A Preferred Stock were estimated with the following assumptions.
202320222021
Expected life, in years 0.74 years1.74 years2.74 years
Expected volatility66.31%65.57%51.64%
Risk-free rate of return5.44%2.89%0.46%
Dividend yield on Class A Common Stock—%1.56%1.34%
Schedule of outstanding nonqualified stock option activity The Company’s outstanding non-qualified stock options as of June 30, 2023 and activity during the fiscal year then ended are presented below:
Shares
(in millions)		Weighted
Average
Exercise
Price		Aggregate
Intrinsic
Value		Weighted
Average
Remaining
Contractual
Term (in years)
Outstanding at July 1, 20225.8 $12.85 
Exercised(0.1)11.08 
Forfeited(0.6)11.42 
Outstanding at June 30, 20235.1 $13.06 
Vested and expected to vest at June 30, 20234.9 $13.13 $— 5.10
Exercisable at June 30, 20234.1 $13.48 $— 4.95
Schedule of stock summary A summary of the aggregated intrinsic value of stock options exercised for fiscal 2023 is presented below:
2023
Intrinsic value of options exercised$0.1 
Schedule of nonvested nonqualified share activity The Company’s non-vested non-qualified stock options as of June 30, 2023 and activity during the fiscal year then ended are presented below:
Shares
(in millions)		Weighted
Average
Grant Date
Fair Value
Non-vested at July 1, 20222.3 $3.14 
Vested(0.9)3.70 
Forfeited(0.4)2.23 
Non-vested at June 30, 20231.0 $3.02 
The Company’s non-vested shares of Series A Preferred Stock as of June 30, 2023 and activity during the fiscal year then ended are presented below:
Shares
(in millions)		Weighted
Average
Grant Date
Fair Value
Non-vested at July 1, 20220.2 $3.65 
Forfeited(0.2)3.65 
Non-vested at June 30, 2023— $— 
Scheduled of outstanding Series A preferred shares The Company’s outstanding Series A Preferred Shares as of June 30, 2023 and activity during the fiscal year then ended are presented below:
Shares
(in millions)		Weighted
Average
Exercise Price		Aggregate Intrinsic ValueWeighted Average Remaining Contractual Term (in years)
Outstanding at July 1, 20221.5 $22.10 
Forfeited(0.5)21.52 
Outstanding at June 30, 20231.0 22.39 
Vested and expected to vest at June 30, 20231.0 $22.39 $— 0.74
Exercisable1.0 $22.39 $— 0.74
Schedule of outstanding RSU and restricted stock activity The Company’s outstanding RSUs as of June 30, 2023 and activity during the fiscal year then ended are presented below:
Shares
(in millions)		Aggregate
Intrinsic
Value		Weighted
Average
Remaining
Contractual
Term
Outstanding at July 1, 202232.4 
Granted17.5 
Settled(14.9)
Cancelled(1.1)
Outstanding at June 30, 202333.9 
Vested and expected to vest at June 30, 202331.0 $381.0 2.26
The Company’s outstanding PRSUs as of June 30, 2023 and activity during the fiscal year then ended are presented below:
Shares
(in millions)		Aggregate
Intrinsic
Value		Weighted
Average
Remaining
Contractual
Term
Outstanding at July 1, 2022— 
Granted1.2 
Settled— 
Outstanding at June 30, 20231.2 
Vested and expected to vest at June 30, 20231.0 12.3 2.31
Schedule of outstanding and non-vested RSU and restricted stock activity The Company’s outstanding and non-vested RSUs as of June 30, 2023 and activity during the fiscal year then ended are presented below:
Shares
(in millions)		Weighted
Average
Grant Date
Fair Value
Outstanding and nonvested at July 1, 202232.0 $8.63 
Granted17.5 9.70 
Vested(15.0)8.79 
Cancelled(1.1)8.02 
Outstanding and nonvested at June 30, 202333.4 $9.38 
The Company’s outstanding and non-vested PRSUs as of June 30, 2023 and activity during the fiscal year then ended are presented below:
Shares
(in millions)		Weighted
Average
Grant Date
Fair Value
Outstanding and nonvested at July 1, 2022— 
Granted1.2 6.62 
Vested— 
Outstanding and nonvested at June 30, 20231.2 $6.62 
Schedule of restricted stock activity The Company’s outstanding restricted stock as of June 30, 2023 and activity during the fiscal year then ended are presented below:
Shares
(in millions)		Aggregate
Intrinsic
Value		Weighted
Average
Remaining
Contractual
Term
Outstanding at July 1, 20220.6 
Granted0.4 
Settled(0.3)
Outstanding at June 30, 20230.7 
Vested and expected to vest at June 30, 20230.6 $7.8 1.95
The Company’s outstanding and non-vested restricted stock as of June 30, 2023 and activity during the fiscal year then ended are presented below:
Shares
(in millions)		Weighted
Average
Grant Date
Fair Value
Outstanding and nonvested at July 1, 20220.6 $6.58 
Granted0.4 6.62 
Vested(0.3)5.94 
Outstanding and nonvested at June 30, 20230.7 $6.94